AJMC October 7, 2023
Noah Stansfield

The program will initially allow 6 sponsors of clinical trials to participate and will provide sponsors with the opportunity for frequent advice and regular communication regarding clinical trial design and other development issues.

The Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program, an FDA initiative newly announced on September 29, 2023, includes provisions that may help smooth and speed up the path to approval for several clinical trials evaluating investigational cell therapies and/or gene therapies for rare disease indications.1

The program, which will initially allow a total of 6 selected sponsors of clinical trials to participate, will provide sponsors with the opportunity for frequent advice and regular communication as needed with regard to clinical trial design and...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Who’s Leading the FDA’s AI Race? Top Medical Specialties and Companies to Watch
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee

Share This Article